NF-κB inhibition protects against tumor-induced cardiac atrophy in vivo

American Journal of Pathology

Volumn 178, Issue 3, 2011, Pages 1059-1068

  Wysong, Ashley ^a   Couch, Marion ^b,c   Shadfar, Scott ^b   Li, Lugi ^b   Rodriguez, Jessica E ^b   Asher, Scott ^b   Yin, Xiaoying ^b,c   Gore, Mitchell ^b   Baldwin, Al ^c,d   Patterson, Cam ^b   Willis, Monte S ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Theralogics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B KINASE; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADENOCARCINOMA; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATROPHY; CACHEXIA; CANCER MODEL; CANCER MORTALITY; CANCER PATIENT; CARDIAC ATROPHY; CONTROLLED STUDY; CYTOKINE RELEASE; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART PROTECTION; HISTOLOGY; IN VIVO STUDY; INFLAMMATION; LEAN BODY WEIGHT; MALE; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SYSTEMIC DISEASE; SYSTOLIC DYSFUNCTION;

EID: 79952763971     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.12.009     Document Type: Article

References (65)

1. Tisdale MJ: Biology of cachexia. J Natl Cancer Inst 1997, 89:1763-1773
2. Inagaki J, Rodriguez V, Bodey GP: Proceedings: causes of death in cancer patients. Cancer 1974, 33:568-573
3. Tisdale MJ: Cachexia in cancer patients. Nat Rev Cancer 2002, 2:862-871
4. Corbett TH, Griswold DP Jr., Roberts BJ, Peckham JC, Schabel FM Jr.: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975, 35:2434-2439
5. Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, Padula F, Spugnini EP, Baldi A, Faiola F, Adamo S, Coletti D: Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer 2010, 10:363
6. Fujita J, Tsujinaka T, Yano M, Ebisui C, Saito H, Katsume A, Akamatsu K, Ohsugi Y, Shiozaki H, Monden M: Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer 1996, 68:637-643 (Pubitemid 26414526)
7. Yasumoto K, Nukaida N, Harada A, Kuno K, Akiyama M, Nakashima E, Fujioka N, Mai M, Kasahara T, Fujimoto-Ouchi K, Mori K, Tanaka Y, Matsushima K: Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res 1995, 55:921-927
8. Vallabhapurapu S, Karin M: Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009, 27:693-733
9. Van Gammeren D, Damrauer JS, Jackman RW, Kandarian SC: The IkappaB kinases IKKalpha and IKKbeta are necessary and sufficient for skeletal muscle atrophy. FASEB J 2009, 23:362-370
10. Cai D, Frantz JD, Tawa NE Jr., Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE: IKKbeta/ NF-kappaB activation causes severe muscle wasting in mice. Cell 2004, 119:285-298 (Pubitemid 39360909)
11. Tisdale MJ: Catabolic mediators of cancer cachexia. Curr Opin Support Palliat Care 2008, 2:256-2561
12. Tisdale MJ: Mechanisms of cancer cachexia. Physiol Rev 2009, 89:381-410
13. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, Guttridge DC: Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004, 114:370-378 (Pubitemid 39071609)
14. Diffee GM, Kalfas K, Al-Majid S, McCarthy DO: Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am J Physiol Cell Physiol 2002, 283:C1376-C1382 (Pubitemid 35178429)
15. Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, Ringel MD, Skipworth RJ, Fearon KC, Hollingsworth MA, Muscarella P, Burghes AH, Rafael-Fortney JA, Guttridge DC: Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005, 8:421-432 (Pubitemid 41579836)
16. Schwarzkopf M, Coletti D, Sassoon D, Marazzi G: Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway. Genes Dev 2006, 20:3440-3452 (Pubitemid 44969161)
17. Weyermann P, Dallmann R, Magyar J, Anklin C, Hufschmid M, Dubach-Powell J, Courdier-Fruh I, Hennebohle M, Nordhoff S, Mondadori C: Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS ONE 2009, 4:e4774
18. McCarthy DO, Whitney P, Hitt A, Al-Majid S: Indomethacin and ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma. Res Nurs Health 2004, 27:174-184 (Pubitemid 38748290)
19. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizuguchi J, Yoshimoto T: Potent antitumor activity of interleukin-27. Cancer Res 2004, 64:1152-1156 (Pubitemid 38176923)
20. Bonetto A, Penna F, Minero VG, Reffo P, Bonelli G, Baccino FM, Costelli P: Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets 2009, 9:608-616
21. van Halteren HK, Bongaerts GP, Verhagen CA, Kamm YJ, Willems JL, Grutters GJ, Koopman JP, Wagener DJ: Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model. J Cancer Res Clin Oncol 2004, 130:211-216 (Pubitemid 38553629)
22. al-Majid S, McCarthy DO: Cancer-induced fatigue and skeletal muscle wasting: the role of exercise. Biol Res Nurs 2001, 2:186-197
23. van Norren K, Kegler D, Argiles JM, Luiking Y, Gorselink M, Laviano A, Arts K, Faber J, Jansen H, van der Beek EM, van Helvoort A: Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice. Br J Cancer 2009, 100:713-722
24. Strassmann G, Masui Y, Chizzonite R, Fong M: Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor J Immunol 1993, 150:2341-2345
25. O'Connell TM, Ardeshirpour F, Asher SA, Winnike J, Yin X, George J, Guttridge DC, He W, Wysong A, Willis MS, Couch ME: Metabolomic analysis of cancer cachexia reveals distinct lipid and glucose alterations. Metabolomics 2008, 4:216-225
26. Willis MS, Ike C, Li L, Wang DZ, Glass DJ, Patterson C: Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ Res 2007, 100:456-459 (Pubitemid 46673255)
27. Willis MS, Rojas M, Li L, Selzman CH, Tang RH, Stansfield WE, Rodriguez JE, Glass DJ, Patterson C: Muscle ring finger 1 mediates cardiac atrophy in vivo. Am J Physiol Heart Circ Physiol 2009, 296:H997-H1006
28. Li HH, Willis MS, Lockyer P, Miller N, McDonough H, Glass DJ, Patterson C: Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J Clin Invest 2007, 117:3211-3223 (Pubitemid 350096979)
29. Willis MS, Schisler JC, Li L, Rodriguez JE, Hilliard EG, Charles PC, Patterson C: Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo. Circ Res 2009, 105:80-88
30. El-Menyar AA: Cytokines and myocardial dysfunction: state of the art. J Card Fail 2008, 14:61-74
31. Depre C, Shipley GL, Chen W, Han Q, Doenst T, Moore ML, Stepkowski S, Davies PJ, Taegtmeyer H: Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med 1998, 4:1269-1275 (Pubitemid 28512107)
32. McMullen JR, Jennings GL: Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 2007, 34:255-262
33. Reuter S, Charlet J, Juncker T, Teiten MH, Dicato M, Diederich M: Effect of curcumin on nuclear factor kappaB signaling pathways in human chronic myelogenous K562 leukemia cells. Ann N Y Acad Sci 2009, 1171:436-447
34. Glass DJ: Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 2005, 37:1974-1984
35. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704-1708 (Pubitemid 33104839)
36. Willis MS, Townley-Tilson WH, Kang EY, Homeister JW, Patterson C: Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease. Circ Res 2010, 106:463-478
37. Rodriguez JE, Schisler JC, Patterson C, Willis MS: Seek and destroy: the ubiquitin-proteasome system in cardiac disease. Curr Hypertens Rep 2009, 11:396-405
38. Willis MS, Schisler JC, Patterson C: Appetite for destruction: e3 ubiquitin-ligase protection in cardiac disease. Future Cardiol 2008, 4:65-75
39. Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T, Sakai K, Inbe H, Takeshita K, Ishimori M, Komura H, Murata T, Lowinger T, Bacon KB: A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 2005, 145:178-192 (Pubitemid 40756522)
40. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S: Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000, 289:1550-1554
41. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC: NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277:16639-16647 (Pubitemid 34967682)
42. Willis MS, Patterson C: Into the heart: the emerging role of the ubiquitin-proteasome system. J Mol Cell Cardiol 2006, 41:567-579 (Pubitemid 44374543)
43. Patterson C, Ike C, Willis PWt, Stouffer GA, Willis MS: The bitter end: the ubiquitin-proteasome system and cardiac dysfunction. Circulation 2007, 115:1456-1463 (Pubitemid 46648383)
44. Mearini G, Schlossarek S, Willis MS, Carrier L: The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta 2008, 1782:749-763
45. Willis MS, Schisler JC, Portbury AL, Patterson C: Build it up-tear it down: protein quality control in the cardiac sarcomere. Cardiovasc Res 2009, 81:439-448
46. Moss NC, Stansfield WE, Willis MS, Tang RH, Selzman CH: IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007, 293:H2248-H2253 (Pubitemid 47605868)
47. Moss NC, Tang RH, Willis M, Stansfield WE, Baldwin AS, Selzman CH: Inhibitory kappa B kinase-beta is a target for specific nuclear factor kappa B-mediated delayed cardioprotection. J Thorac Cardiovasc Surg 2008, 136:1274-1279
48. Soysa NS, Alles N, Shimokawa H, Jimi E, Aoki K, Ohya K: Inhibition of the classical NF-kappaB pathway prevents osteoclast bone-resorbing activity. J Bone Miner Metab 2009, 27:131-139
49. Long YM, Chen K, Liu XJ, Xie WR, Wang H: Cell-permeable Tat-NBD peptide attenuates rat pancreatitis and acinus cell inflammation response. World J Gastroenterol 2009, 15:561-569
50. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, Okabe K, Ohya K, Ghosh S: Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004, 10:617-624 (Pubitemid 38796853)
51. Shibata W, Maeda S, Hikiba Y, Yanai A, Ohmae T, Sakamoto K, Nakagawa H, Ogura K, Omata M: Cutting edge: the IkappaB kinase (IKK) inhibitor. NEMO-binding domain peptide, blocks inflammatory injury in murine colitis J Immunol 2007, 179:2681-2685
52. Tas SW, Vervoordeldonk MJ, Hajji N, May MJ, Ghosh S, Tak PP: Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res Ther 2006, 8:R86
53. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, Furlow JD, Bodine SC: The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab 2008, 295:E785-E797
54. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004, 14:395-403 (Pubitemid 38591410)
55. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL: IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004, 287:E591-E601 (Pubitemid 39242684)
56. Attaix D, Baracos VE: MAFbx/Atrogin-1 expression is a poor index of muscle proteolysis. Curr Opin Clin Nutr Metab Care 2010, 13:223-224
57. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R, Hung MC: IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004, 117:225-237 (Pubitemid 38496242)
58. Dan HC, Adli M, Baldwin AS: Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Res 2007, 67:6263-6269 (Pubitemid 47037508)
59. Hutti JE, Turk BE, Asara JM, Ma A, Cantley LC, Abbott DW: IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol Cell Biol 2007, 27:7451-7461 (Pubitemid 350033652)
60. Xia Y, Padre RC, De Mendoza TH, Bottero V, Tergaonkar VB, Verma IM: Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci U S A 2009, 106:2629-2634
61. Raffaello A, Milan G, Masiero E, Carnio S, Lee D, Lanfranchi G, Goldberg AL, Sandri M: JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy. J Cell Biol 2010, 191:101-113
62. Ferreira R, Neuparth MJ, Vitorino R, Appell HJ, Amado F, Duarte JA: Evidences of apoptosis during the early phases of soleus muscle atrophy in hindlimb suspended mice. Physiol Res 2008, 57:601-611
63. Siu PM, Pistilli EE, Murlasits Z, Alway SE: Hindlimb unloading increases muscle content of cytosolic but not nuclear Id2 and p53 proteins in young adult and aged rats. J Appl Physiol 2006, 100:907-916 (Pubitemid 43671547)
64. Sakuma K, Yamaguchi A: Molecular mechanisms in aging and current strategies to counteract sarcopenia. Curr Aging Sci 2010, 3:90-101
65. Mouisel E, Vignaud A, Hourde C, Butler-Browne G, Ferry A: Muscle weakness and atrophy are associated with decreased regenerative capacity and changes in mTOR signaling in skeletal muscles of venerable (18-24-month-old) dystrophic mdx mice. Muscle Nerve 2010, 41:809-818